

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number  
**WO 02/43778 A2**

(51) International Patent Classification<sup>7</sup>: **A61L**

(74) Agents: **JAMES, John, Christopher** et al.; Edwards Lifesciences LLC, One Edwards Way, Irvine, CA 92614 (US).

(21) International Application Number: PCT/US01/46088

(22) International Filing Date:  
1 November 2001 (01.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(30) Priority Data:  
60/244,889 1 November 2000 (01.11.2000) US  
09/930,619 15 August 2001 (15.08.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **EDWARDS LIFESCIENCES CORPORATION** [US/US]; One Edwards Way, Irvine, CA 92614 (US).

(72) Inventors: **CUNANAN, Crystal**; 25581 Althea Avenue, Mission Viejo, CA 92691 (US). **DINH, Tan**; 9070 Buttercup Avenue, Fountain Valley, CA 92653 (US). **SARNER, Chris, H.**; 25216 Pike Road, Laguna Hills, CA 92653 (US). **HELMUS, Michael, N.**; 3733 Cedar Avenue, Long Beach, CA 90807 (US). **CABLING, Christine**; 1881 Mitchell #87, Tustin, CA 92780 (US).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS FOR PREPARATION OF BIOPROSTHETIC TISSUE AND IMPLANTABLE DEVICES COMPRISING SUCH BIOPROSTHETIC TISSUE

(57) Abstract: The present invention provides methods of inactivating and removing infectious agents from tissues of use in bioprosthetic devices. The methods include the removal and blockage of binding sites on the tissues for the infectious agents. Also provided are methods for blocking a site on an infectious agent that binds to a site on the tissue. The invention also provides a method for preventing or reducing the calcification of a bioprosthetic tissue. The method includes removing or blocking a phospholipid calcium nucleation site from the tissue.



**WO 02/43778 A2**

**METHODS FOR PREPARATION OF BIOPROSTHETIC  
5 TISSUE AND IMPLANTABLE DEVICES COMPRISING SUCH  
BIOPROSTHETIC TISSUE**

**CROSS-REFERENCE TO RELATED APPLICATIONS**

The present application claims priority to U.S. Provisional  
10 Application No. 60/244,889, filed on November 1, 2000, and is a continuation-in-  
part of U.S. Patent Application No. 09/930,619, filed on August 15, 2001, the  
disclosures of both of which are incorporated herein by reference in their entirety  
for all purposes.

**15 BACKGROUND OF THE INVENTION**

Implantable xenografts and prosthetic devices are typically  
sterilized prior to implantation in an intended recipient. Sterilization is required to  
ensure that the devices do not introduce potential pathogens, or other biologically  
detrimental agents into the intended recipient. Sterilization is particularly relevant  
20 where biomaterials from human or other mammalian donors are constituents of the  
graft or device. Examples of biological tissues that have been used to form  
implantable bioprostheses include cardiac valves, blood vessels, skin, dura mater,  
pericardium, ligaments, and tendons.

Device components are sterilized individually prior to assembling  
25 the device or, alternatively, they are sterilized by the process of "terminal  
sterilization". In the terminal sterilization process, the device is sterilized  
following its construction, i.e., after all the components have been combined with  
one another in the device. Both processes may be used in combination to ensure  
complete sterilization of the graft or device. A variety of physical or chemical  
30 methods have been developed for use in sterilization and include, for example,  
exposure to chemicals or heat, or exposure to ionizing or non-ionizing radiation.

Historically, for infectious agents such as bacteria, there are well established methods of control that involve different forms of sterilization, for example, steam sterilization, dry sterilization, pasteurization, sterile filtration, radiation inactivation, and the like. With viruses, there are also established  
5 methods which involve lowering of the pH to 4.0 or below, or use of organic solvents in high concentrations. Extended periods of heating at 60° C also may be used. In addition, UV radiation treatment, formaldehyde and specific antiviral agents have been employed to mitigate the potential harm associated with viruses.

These methods, however, have inherent problems and may have  
10 adverse effects on biological tissue. Consequently, most of the methods are inappropriate for bioprosthetic devices incorporating mammalian tissue. Further, many of the methods are not effective for preventing or inhibiting harm associated with certain classes of infectious agents, such as prions.

Exemplary sterilization methods include treating prosthesis and  
15 graft components with chemical reagents. The chemical reagents themselves, or reaction byproducts derived from the reagents, can be harmful to the intended recipient of the prosthetic device. Accordingly, such chemicals must be removed prior to implantation of the devices. Common chemical sterilizing agents include ethylene oxide and formaldehyde, both of which are alkylating agents and,  
20 therefore, can modify and inactivate biologically active molecules. *See, Davis et al., (1973) "Microbiology, 2nd Ed.", Harper and Row, Publishers.*

Other methods of sterilizing device components include exposing the device or components thereof to heat, ionizing radiation, or plasma. *See, Moulton et al., U.S. Pat. No. 5,084,239.* Exposing a device, which includes  
25 biological components (e.g. proteins, cells, tissues), to elevated temperatures, radiation, or plasma is not desirable because proteins and other biological materials can be denatured and subsequently inactivated or weakened by exposure to these forms of energy. Although the sterilization of objects by exposure to ionizing and non-ionizing radiation obviates the necessity of adding potentially toxic chemicals,  
30 the radiation energy and/or its byproducts, including oxygen free radicals, are competent to modify protein conformation and so can damage or destroy proteins, cells, and tissue. In addition, exposure of some medically important polymers, for example, polyurethane or polymethylmethacrylate to gamma radiation can result in

immediate and long term physical changes to the polymer. Moreover, irradiation with gamma or beta rays does not destroy all pathogens with certainty. Indeed, certain viruses are radiation resistant. Thus, alternatives to sterilizing xenografts and biologically derived components of prosthetic devices with harsh chemicals and radiation are being avidly sought.

A number of infectious agents pose a threat to the safety of implantable bioprosthetic devices. Among these are bacteria, viruses, retroviruses, fungi, mycoplasma, and prions. Various proteins and nucleic acids may also act as infectious agents. Of increasing concern is the presence of infectious prions in biologically derived materials used for xenografts and prosthetic devices. The widespread occurrence of prion-related disease and the possibility of interspecies transmission has serious implications for the biotechnology industry, which derives many of its products from mammalian tissue. *See, Di Martino Biologicals* **21**: 61-66 (1993). Concerns about the safety of mammalian tissue products has led to studies on the inactivation of prions. These studies indicate that prions are more resistant toward inactivation than more conventional pathogens such as viruses or bacteria. Thus, relatively harsh conditions are required to decontaminate prion-containing biological materials. The only methods currently known to disinfect prion contaminated biological preparations are prolonged autoclaving at 130° C or above, and treatment with concentrated sodium hydroxide solution. These methods have been recommended for routine inactivation of prions. *See, Department of Health and Social Security Circular* **84**: 16 (1989). It has also been reported that 100 kD cutoff ultrafiltration in combination with treatment with 6M urea results in decontamination of prion containing preparations. *See, Pocchiari et al., Arch. Virol.* **98**: 131-135 (1988). Other methods capable of lowering prion activity include treatment with organic solvents, detergents, protein-denaturing agents, chaotropic salts and phenol. *See, Millson et al., in Prusiner and Hadlow, eds. SLOW TRANSMISSIBLE DISEASES OF THE NERVOUS SYSTEM, vol. II. New York: Academic Press* 409-424 (1979); *Prusiner et al., Proc. Natl. Acad. Sci. USA* **78**: 4606-4610 (1981); *Kimberlin et al., J. Neurol. Sci.* **59**: 390-392 (1983); *Walker et al., Am. J. Public Health* **73**: 661-665 (1983); and *Brown et al., J. Infect. Dis.* **153**: 1145-1148 (1986). Each of the above-recited methods is generally inappropriate for treating tissues.

Additional methods of removing prions from biological material include removing prions from solution by directing the solution through an anion-exchange chromatography column. Gawryl *et al.*, in U.S. Patent No. 5,808,011. Filtration methods, however, are not suitable for treating whole tissues, where the structural integrity of the tissue membrane must be preserved.

In U.S. Patent No. 5,780,288, Rohwer *et al.* describe a method for destroying infectivity in a proteinaceous mixture such as animal feed. This method involves the application of harsh alkali and heat treatments, and while this may be effective for disinfecting animal feed, the method is not appropriate for treating bioprosthetic tissue.

In U.S. Patent No. 5,756,678, Shenoy *et al.* describe a method for treating solubilized collagen to inactivate prions and other infective agents, via the application of sodium hydroxide. Shenoy *et al.* do not, however, suggest that this method would be effective for treating bioprosthetic tissue.

Cashman *et al.*, in PCT publications WO 97/45746, WO 00/78344, and WO 01/00235, discuss methods for treating prion infectivity in biological tissue that include contacting the tissue with prion binding proteins such as protocadherins and antibodies. methods making use of other compounds to remove or inactivate infectious materials in tissues are not disclosed.

Reichl, in U.S. Patent No. 5,633,349 describes a method for inactivating prions and other infectious agents in plasma by contacting the plasma with a chaotropic agent such as urea or sodium thiocyanate. Reichl does not discuss a method for treating bioprosthetic tissue designed as a transplant graft.

In U.S. Patent No. 6,150,172, Alpert *et al.* discuss a method for extracting infectious prion from a biological material using an extraction solvent such as a polar organic solvent. Alpert *et al.* do not describe a method for treating bioprosthetic tissue for a transplant graft.

Narotam *et al.*, in U.S. Patent No. 5,997,895, and Doillon *et al.*, in U.S. Patent No. 6,197,935, describe methods for rendering collagen preparations free from viral and prion infectivity. As these methods involve intensive mechanical disruption of the collagen material, they would not be suitable for treating bioprosthetic tissue as contemplated by the present invention.

Prusiner *et al.*, in WO 00/43782, discuss a method for removing prion from a liquid sample. As described, the liquid sample is flowed across a solid surface that contains a prion complexing agent. Removal methods such as these are not suitable for treating whole tissue, where the structural integrity of the tissue membrane must be preserved.

A recent survey of prion inactivation methods discusses approaches such as moist heat (autoclaving), filtration, formaldehyde, heat, phenols, irradiation, potassium permanganate, sodium dodecyl sulfate, sodium hydroxide, sodium perchlorate, and sodium hypochlorite. The survey indicates that while several avenues are being investigated, the search continues for a process that can substantially minimize the risk of infection. *See*, Cox, Institute for International Research Conference, March 15-16, 1999, San Diego.

In addition to binding sites for infectious materials, tissues of use in bioprosthetic devices often include nucleation sites for calcium, leading to calcification and premature failure of the device. Calcification is an important factor in clinical dysfunction of bioprosthetic heart valves (Schoen *et al.*, *J Card Surg* **9**[suppl]:222-227 (1994)). Morphological examination of explanted bioprostheses indicates that calcification is frequently associated with collagen fibrils, organelles such as mitochondria and nuclei of devitalized cells (including connective tissue cells of the leaflets, and cells of the muscle shelf, and aortic wall of porcine aortic valves), thrombi, and vegetations (Schoen FJ, *et al.*, *J Card Surg* **9**[suppl]:222-227 (1994); Schoen FJ, *et al.*, *J Biomed Mater Res* **47**:439-465 (1999); Ferrans YJ, *et al.*, *Hum Pathol* **18**:586-595 (1987)). It has been postulated that the onset of calcification could originate from an electrostatic attraction between the acid phospholipids of the connective tissue and calcium (Herrero *et al.*, *J Mat Sci Mat Med* **2**:86-88 (1991)), although no method of preventing the postulated attraction was provided in this study.

As discussed above, infectivity and calcification of bioprosthetic tissues has detrimental effects upon the patient into whom these tissues are implanted. Presently, there is no widely-accepted method for eliminating the sites of calcium nucleation in a tissue. Moreover, the extreme conditions required to eliminate infectivity, and particularly prion infectivity, in biomaterials are typically incompatible with methods intended to preserve the useful activity and structure of

these materials. The harsh conditions of prior methods are particularly deleterious to mammalian tissue, resulting in the denaturation of functional and structural components of the tissues.

There is an ongoing need for methods of eliminating or retarding  
5 calcification of implanted bioprosthetic tissue and for treating or preventing infectivity in mammalian tissue that does not compromise the integrity of these desirable biomaterials. The present invention meets these and other needs.

### BRIEF SUMMARY OF THE INVENTION

10 There has been a recognized absence, in the tissue treatment arts, of mild chemical and enzymatic methods for preventing or reducing infectivity in bioprosthetic tissues. The present invention provides an effective protocol for preparing mammalian tissue for incorporation into a bioprosthetic device. The invention is based on the discovery that mild chemical or enzymatic treatments are  
15 effective at eliminating or inhibiting a surprisingly high level of infectivity from tissue or biological samples. Further, these procedures do not significantly degrade or denature tissue proteins, and thus tissues prepared under this protocol are well suited for use in bioprosthetic devices.

The methods of the present invention are effective, not only for  
20 preventing infectious agents from binding to the tissue, but also for removing infectious agents from tissue under conditions that are notably more mild than previous art-recognized methods. Although the methods described herein are of general applicability, the present invention particularly concerns a method for reducing or eliminating infectious agent contamination in bioprosthetic tissue  
25 preparations.

Thus, in a first aspect, the present invention provides a method of eliminating or reducing infection in a bioprosthetic tissue. Tissue cells typically have binding sites on their surface that can be recognized by infectious agents. Binding sites may also be recognized by other unwanted substances, such as  
30 certain enzymes, proteins, protein precursors, and the like. Often, these binding sites contain phospholipid components. Therefore, the method includes removing phospholipid binding sites located in the tissue, so that infectious agents or other unwanted substances are prevented or inhibited from binding to the tissue.

In a second aspect, the present invention provides a method of eliminating or reducing infection in a bioprosthetic tissue. While binding sites may contain phospholipid components, they may optionally or also contain protein or polysaccharide moieties. Therefore, the method also includes removing protein  
5 and/or polysaccharide binding sites located in the tissue, so that infectious agents or other unwanted substances are prevented or inhibited from binding to the tissue.

In a third aspect, the present invention provides a method of eliminating or reducing infection in a bioprosthetic tissue. The method includes blocking an infectious agent binding site contained in the tissue, so that infectious  
10 agents are prevented or inhibited from binding to the tissue.

In a fourth aspect, the present invention provides a method of eliminating or reducing infection in a bioprosthetic tissue. The method comprises contacting the tissue with a preparation having binding affinity for the infectious agent, thereby blocking the agent from infecting or contaminating the tissue.  
15 Thereafter, the binding agent may be optionally washed from the tissue in an extraction procedure, thereby removing the agent from the tissue.

Similar to the absence of mild treatment methods to reduce or eliminate infectivity in bioprosthetic tissues, the art lacks a method of treating tissues to remove or block the sites of calcium nucleation. Thus, in a further  
20 aspect, the present invention provides a method of preventing or retarding calcification in a bioprosthetic tissue. The present inventors have found that calcium nucleation correlates with the concentration in a tissue of phospholipid components. Therefore, the invention provides a method of removing phospholipid calcium nucleation sites located in the tissue, so that calcium or other  
25 ions are prevented or inhibited from binding to the tissue.

In a sixth aspect, the present invention provides a method of preventing or retarding calcification of a bioprosthetic tissue. The method includes blocking a calcium nucleation site contained in the tissue, so that calcium is prevented or inhibited from binding to the tissue.

30 The artisan will appreciate that in addition to treating bioprosthetic tissues, the methods of the present invention are well suited for disinfecting, sterilizing, decontaminating, or otherwise preventing contamination in a wide variety of medical instruments and laboratory work surfaces.

Other objects and advantages of the present invention will be apparent from the detailed description that follows.

## DETAILED DESCRIPTION OF THE INVENTION AND THE PREFERRED EMBODIMENTS

### Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

As used herein, the term "remove" refers to a process of purging a selected agent from a tissue or other biological sample. Typically, this means eliminating a binding or nucleation site or an infectious agent from a bioprosthetic tissue.

The term "block" refers to a process of inhibiting or eliminating any propensity of association between an infectious agent or calcium and the corresponding binding or nucleation site, respectively. This is generally accomplished by the administration of a blocking agent. For example, blocking a particular infectious agent renders it less able to adhere to a complementary binding site. Alternatively, blocking a particular binding site renders it less able to adhere to an associated infectious agent. Similarly, blocking a calcium nucleation site renders that site less able to bind to calcium. Generally, it is the physical presence of the blocking agent that interferes with the association between the infectious agent and the binding site, or the calcium and the nucleation site. In some instances, a blocking agent will competitively bind to a selected binding site of an infectious material, or to a site of calcium nucleation.

While a blocking agent may physically or chemically obstruct association between the binding site and the infectious agent or calcium, the invention also contemplates other mechanisms of action. For example, the

blocking agent may additionally or alternatively act to modify or otherwise change the binding site, the infectious agent, or both, so that association between the two is weakened or eliminated. Accordingly, the continued presence of the blocking agent may or may not be required to obstruct or interfere with the association. The  
5 above-discussion is generally applicable to the aspects of the invention directed to prevention or reduction of tissue calcification. The focus on infectious agents is for clarity of illustration only.

“Infectious agent” refers to an agent targeted by the process of the invention, and include, without limitation, viruses, bacteria, mycobacteria,  
10 mycoplasma, fungi, prions, prion pre-cursors, and constituents thereof. The term “infectious agent” also includes DNA, RNA, nucleic acids, proteins, peptides, amino acids, and carbohydrates. Further, this term refers to any molecule or composition of biological origin capable of serving as a causal agent of disease.

As used herein, the term “about” or “approximately” means within  
15 20%, preferably within 10%, and more preferably within 5% of a given value or range.

Examples of “biological material” from human or animal include, but are by no means limited to, tissue such as brain, muscle (including heart), liver, appendix, pancreas, gastrointestinal tract organs, skin, bone, cartilage, tendon,  
20 ligament, connective tissue, and lymphoid tissue such as thymus, spleen, tonsil, lymph nodes, and the like. Alternatively, the biological material may be a biological fluid. The term biological fluid refers to cerebrospinal fluid, blood, serum, plasma, milk, urine, saliva, tears, mucous secretions, sweat, semen and bodily fluids comprising these components. It also refers to culture fluid (or  
25 culture medium) used in the production of recombinant proteins or containing cells in suspension prior to transplantation. Also encompassed by the term “biological materials” are products made from human or animal organs or tissues, including serum proteins (such as albumin and immunoglobulin), hormones, food and processed food products, nutritional supplements, bone meal, animal feed,  
30 extracellular matrix proteins, gelatin, and other human or animal by products used in manufacturing or final goods. The term additionally refers to any material that can be found in a human or animal that is susceptible to infection or that may carry or transmit infection.

The term “medical instrument” refers to a wide variety of devices used in surgical and medical procedures and in fabricating bioprosthetic devices. These include, but are not limited to, catheters, cannulas, dialysis or transfusion devices, shunts, stents, sutures, scissors, needles, stylets, devices for accessing the interior of the body, implantable ports, blades, scalpels. The term “medical instrument” is intended to encompass any type of device or apparatus that is used to contact a patient, and in particular used to contact the interior of the patient. The term also encompasses any device or tool used in the preparation or manufacture, or otherwise comes into contact with, a biological tissue.

“Laboratory work surface” refers to any work surface used by clinicians, surgeons, physicians, researchers, manufacturers, or anyone involved in the preparation, use, manufacture, or packaging of biological tissues or medical instruments that are intended for use in a patient. As work surfaces present a potential source of contamination, the methods of the present invention are well suited for treating these surfaces as well.

“Binding site” refers that portion of the biological material that forms an association with an infectious agent. For example, a binding site may include phospholipid, protein, and/or polysaccharide components. The term “binding site” also refers to that portion of the biological material that forms an association with certain enzymes, proteins, infectious agents, or other selected biomolecules.

“Nucleation site” refers to that portion of the biological material that forms an association with calcium or other metal ions. The calcium nucleation sites may include phospholipid, protein, and/or polysaccharide components.

The terms “prion,” “prion protein,” “PrP protein,” “PrP,” and like are used interchangeably herein and shall mean both the infectious particle form PrP<sup>Sc</sup> known to cause diseases (spongiform encephalopathies) in humans and animals as well as the noninfectious form PrP<sup>C</sup> which, under appropriate conditions, is converted to the infectious PrP<sup>Sc</sup> form. The term prion will also refer to fragments or proteolytic digestion products of the complete form of the prion protein. The term prion is a contraction of the words “protein” and “infection.”

Infectious prion protein is much less susceptible to proteolysis than noninfectious prion protein. For example, treatment of a biological material with a

proteinase, particularly proteinase-K, has been shown to digest noninfectious prion protein, but not infectious prion protein.

Prion protein is a native protein expressed in neural tissue, particularly the brain and at lower levels in lymphoid tissues and all other tissues.

5 Prion protein generally occurs in PrP dimers, and is distinct from bacteria, viruses and viroids.

Typically, prions are encoded by a *PrP* gene. The terms "*PrP* gene," "*prion* gene," and the like are used interchangeably to describe genetic material which expresses proteins including known polymorphisms and pathogenic mutations thereof, it being recognized that the term includes other such *PrP* genes that are yet to be discovered. The term "*PrP* gene" refers generally to any gene of any species which encodes any form of a PrP protein. Some commonly known PrP sequences are described in Gabriel *et al.*, *Proc. Natl. Acad. Sci. USA* **89**:9097-9101 (1992); U.S. Patents 5,565,186; 5,763,740; 5,792,901; and PCT Publication  
10 W097/04814, incorporated herein by reference to disclose and describe such sequences. The protein expressed by such a gene can assume either a PrP<sup>C</sup> (non-disease) or PrP<sup>Sc</sup> (disease) form. Certain mutations of the *prion* gene in some individuals appear to predispose prion protein to adopt the pathogenic conformation.

20 The term "causal agent" is intended to refer to an agent which either causes a disease or is a necessary component of a disease-producing system. Causal agents associated with a wide variety of diseases can be treated by the method of the present invention. For instance, the prion is a causal agent of several central nervous system diseases which are discussed below. The prion can be, for  
25 example, a protein, such as a post-translationally modified PrP protein, or it can be a protein complexed with an informational molecule, such as a polynucleotide, for example, a polydeoxy-ribonucleotide complexed with a post-translationally modified PrP protein.

"Prion disease" refers to one of several rapidly progressive, fatal, and untreatable brain degenerative disorders. These are generally considered to be transmissible spongiform encephalopathies (TSE), a group that includes, but  
30 without limitation: Creutzfeldt-Jakob disease (CJD), new variant CJD, Kuru, Gerstmann-Straussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI) in

humans, scrapie in sheep and goats, spongiform encephalopathy in cattle “mad cow disease”, as well as recently described prion diseases in cats, and other ruminants. Prion infection has also been observed in chicken, mink, pigs, mice, hamsters, guinea pigs, eland, elk, gemsbok, greater kudu, muledeer, nyala, oryx,  
5 and various avian species. Prion infection from these and other sources can be treated by the method of the present invention.

Generally, prion protein is found in vertebrates. Alternatively, prion protein can also be produced during fermentation processes with eukaryotic cells. It may be expressed as a recombinant prion protein. Of greater concern is  
10 the possibility of incidental expression of endogenous prion protein by cells that have been recombinantly modified to express another protein. This possibility is more likely if the cells are of neural origin, such as PC12 cells. In this case, the biological material may be a fermentation product, e.g., recombinant protein.

The phrase “substantially free of infectious agent” means that the  
15 product does not contain infection-effective amounts of infectious agent.

For the purposes of the present invention, the terms “surfactant” and “detergent” are used interchangeably and both shall refer to compounds or ions that (1) are made of groups of opposing solubility tendencies, such as an oil-soluble hydrocarbon chain and a water-soluble ionic group, (2) are soluble in at  
20 least one phase of a liquid system, (3) have a concentration at a phase interface that is greater than its concentration in the bulk of the solution when at equilibrium and in solute form, (4) form oriented monolayers at phase interfaces, (4) form micelle aggregates at the critical micelle concentration, and (5) exhibit combinations of cleaning, foaming, wetting, emulsifying, solubilizing, and dispersing properties  
25 when in solution. Perhaps the hallmark feature of a surfactant is the presence of two structurally dissimilar groups within a single molecule. Further defining features of surfactants can be found in KIRK-OTHMER’S “ENCYCLOPEDIA OF CHEMICAL TECHNOLOGY,” Third Edition, Vol. 22, pp. 332-432, which is hereby incorporated by reference.

30

### **The Methods**

The present invention provides methods for removing or blocking a binding site present in mammalian tissue. The binding site can be one to which an

infectious agent binds, or it may be a nucleation site for calcium, which is causally related to calcification of the implanted tissue. The present invention also provides methods for removing or blocking an infectious agent or other protein associated with mammalian tissues. The discussion that follows is generally focused on the prevention or reduction of infection in a bioprosthetic tissue, however, this discussion is broadly applicable to the aspects of the invention in which a calcium nucleation site is removed from a tissue or the ability of the site to bind to calcium is reduced or eliminated. The focus on infective materials is for clarity of illustration and is not intended to be limiting of the scope of the invention.

In a first aspect, the present invention provides a method for eliminating or reducing infectivity in a biological material. A related embodiment provides a method for eliminating or reducing prion infection in a bioprosthetic tissue. The method includes removing a prion protein binding site contained in the tissue so that prion protein is prevented or inhibited from binding to the tissue.

Typically, the invention is applicable to combating prion protein infection, and for preventing its transmission during tissue grafts. The invention is also applicable to combating a wide variety of bacteria including, but not limited to, *Pseudomonas aeruginosa*, *Campylobacter upsaliensis*, and *Escherichia coli*, and for preventing their transmission during implantation of tissue grafts and other bioprosthetic devices.

Bacteria have been implicated in various diseases. Often, phospholipids are implicated as the receptor binding sites recognized by these opportunistic pathogens. For example, two phospholipids in rabbit corneal epithelium, phosphatidylserine and phosphatidylinositol, provide bacterial binding sites. See, e.g., Panjwani *et al.*, "Pathogenesis of Corneal Infection: Binding of *Pseudomonas aeruginosa* to Specific Phospholipids," *Infect. Immun.* **64**(5): 1819-1825 (1996). Phosphatidylethanolamine, gangliotetraosylceramide (Gg4), and phosphatidylserine have been shown to be exhibit binding activity to infectious agents. See, e.g., Sylvester *et al.*, "Adherence to Lipids and Intestinal Mucin by a Recently Recognized Human Pathogen, *Campylobacter upsaliensis*," *Infect. Immun.* **64**(10): 4060-4066 (1996). Further, phosphatidylethanolamine is recognized as exhibiting binding activity to other bacterial pathogens. See, e.g., Foster *et al.*, "Phosphatidylethanolamine Recognition Promotes Enteropathogenic

*E. coli* and Enterohemorrhagic *E. coli* Host Cell Attachment,” *Microb. Pathog.* 27(5): 289-301 (1999).

In a preferred embodiment, the method of the present invention provides eliminating or inhibiting infectivity in a tissue by contacting the tissue with a composition that removes one or more phospholipid infectious agent binding sites contained in the tissue. In yet another preferred embodiment, the present invention provides a method for preventing or reducing the calcification of a bioprosthetic tissue by contacting the tissue with a composition that removes one or more phospholipid calcium nucleation sites in the tissue.

In a related aspect, the present invention provides a method for eliminating or reducing the presence of various membrane-bound enzymes, proteins, or precursor proteins having a biological function that could adversely affect the performance and durability of a tissue derived bioprosthesis. For example, alkaline phosphatase activity has been linked to initiation of calcification in small animal models. Phospholipids have been shown to play a role in the binding of this enzyme to cell membranes. See, e.g., Low *et al.*, “Role of Phosphatidylinositol in Attachment of Alkaline Phosphatase to Membranes,” *Biochem.* 19(17): 3913-3918 (1980). In a preferred embodiment, the present invention provides a method for treating a tissue by removing or blocking one or more phospholipids that function as the binding sites for this enzyme.

Likewise, the enzyme acetylcholinesterase is believed to bind to the plasma membrane via a phospholipid, particularly phosphatidylinositol. See, e.g., Futerman *et al.*, “Identification of Covalently Bound Inositol in the Hydrophobic Membrane-Anchoring Domain of Torpedo acetylcholinesterase,” *Biochem. Biophys. Res. Commun.* 129(1): 312-317 (1985), and Cross, “Eukaryotic Protein Modification and Membrane Attachment Via Phosphatidylinositol,” *Cell* 48: 179-181 (1987). In a preferred embodiment, the present invention provides a method for treating tissue by removing the phospholipid that functions as the binding site for acetylcholinesterase.

Similarly, Thy-1 is a protein associated with immune cell recognition. Phospholipids have been shown to play a role in the binding of this protein. See, e.g., Low *et al.*, “Phosphatidylinositol is the Membrane-Anchoring Domain of the Thy-1 Glycoprotein,” *Nature* 318(6041): 62-64 (1985). In a

preferred embodiment, the present invention provides a method for treating a tissue by removing the phospholipid that functions as the binding site for Thy-1.

Similarly, prion protein is an infectious agent of considerable interest. Phospholipids are believed to play a role in the binding of this protein.

5     See, for example, Di Martino *et al.*, "The Consistent Use of Organic Solvents for Purification of Phospholipids from Brain Tissue Effectively Removes Scrapie Activity," *Biologicals* **22**(3):221-225 (1994). It is believed that prion is attached to the cell wall membrane via the phosphatidylinositol moiety of a glycosyl-phosphatidylinositol (GPI) molecule. In a preferred embodiment, the present invention provides a method for treating a tissue by removing the phospholipid that functions as the binding site for prion protein.

10     In a preferred embodiment, the tissue with which the present method is practiced includes substantially any mammalian tissue that is useful in preparing a prosthetic device having a biological component thereto. For example, in one embodiment, the tissue is derived from an organ. In another embodiment, the tissue is selected from nerve tissue, glandular tissue (e.g., lymphatic tissue), respiratory tissue, digestive tissue, urinary tract tissue, sensory tissue (e.g., cornea, lens, etc.), and reproductive tissue. In a related embodiment where the biological material is a biological fluid, however, addition of liquid is not likely to be necessary, unless to dilute the ionic strength of the biological fluid to permit miscibility of the extraction solvent.

15     In presently a preferred embodiment, the tissue is selected from muscle tissue, adipose tissue, epithelial tissue and endothelial tissue. In particularly preferred embodiments, the tissue is selected from myocardial tissue and vascular tissue. In a related embodiment, the tissue is selected from the group including, without limitation, heart valve, venous valve, blood vessel, ureter, tendon, dura mater, skin, pericardium, intestine (e.g., intestinal wall), or peristium. In a particularly preferred embodiment, the tissue is derived from bone, cartilage (e.g. meniscus), tendon, ligament, or any other connective tissue.

30     As the source of the material used for this purpose may vary with regard to both tissue type, the source may also vary with regard to species type (autologous, homologous or heterologous tissue). The artisan will appreciate that

the methods of the present invention may be used with bioprosthetic devices that include one or more types of tissues or materials.

In a preferred embodiment where the biological material is a solid tissue or product, it may first be suspended in an aqueous solution so that it will be suitable for the extraction process. For example, brain tissue may be suspended in sucrose solution (e.g., 0.32 M sucrose) at 10% weight to volume. Other hypotonic or isotonic solutions include 5% dextrose, phosphate buffered saline, tri-buffered saline, HEPES-buffered saline, or any of the foregoing buffers. The biological material in the aqueous solution can also be homogenized, ground, or otherwise disrupted to maximize contact between the treatment agents and the biological material.

In a particularly preferred embodiment, the biological material will form part or all of a bioprosthetic tissue that is designed and intended for implantation into a graft recipient.

In a preferred embodiment, the infectious agent binding or calcium nucleation site includes one or more phospholipids. In related embodiments, the binding or nucleation site is from the group including, without limitation, phosphatidic acid (PA), phosphoethanolamine, phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylcholine (PC), and sphingomyelin (SM). In further related embodiments, the binding or nucleation site is from the group including phosphatidylethanolamine (PE), and gangliosylceramide (Gg4).

In an exemplary embodiment, the method includes contacting the bioprosthetic tissue with a surfactant. In a particularly preferred embodiment, the surfactant is Tween 80. In another exemplary embodiment, the method includes contacting the bioprosthetic tissue with a preparation containing a surfactant, as well as a denaturing agent, such as a protic solvent. In a particularly preferred embodiment, the surfactant is Tween 80, and the protic solvent is ethanol or isopropanol. In related embodiment, the preparation further contains a cross linking agent, such as an aldehyde, and the aldehyde is preferably formaldehyde or glutaraldehyde.

Presently preferred aldehydes include both mono- and poly-aldehydes. Aldehydes of use in practicing the present invention include any aldehyde, either substantially pure or containing additives, that prevents or inhibits

infectivity in mammalian tissue. Although any aldehyde that has desirable characteristics for a particular application can be used to practice the present invention, certain aldehydes are presently preferred.

Preferred aldehydes include one or more compounds of the group  
5 consisting of acetaldehyde, butyraldehyde, isobutyraldehyde, propionaldehyde,  $\alpha$ -methylpropionaldehyde, 2-methylbutyraldehyde, cyclopentanecarbaldehyde, benzaldehyde, caproaldehyde, carbaldehyde, and the like.

In an preferred embodiment, the methods of the present invention use formaldehyde. The tissue is treated with substantially any amount of  
10 formaldehyde that provides the sought after results. The determination of the correct amount of formaldehyde needed for a particular application is well within the abilities of those of skill in the art. For example, a tissue is extracted one or more times with formaldehyde and the extracted material is collected. The amount of infectious material or chemical agent removed by the extraction is preferably  
15 determined. When the formaldehyde ceases to remove infectious agent and/or chemical agent from the tissue an end point is reached, which is indicative of the amount of formaldehyde necessary to remove the particular agent from the tissue.

In a preferred embodiment utilizing formaldehyde, the tissue is treated with a formaldehyde solution containing from about 1% to about 10%  
20 formaldehyde. The extraction can be performed as a single step. Alternatively, the extraction can be performed as a series of sequential steps. At the end of each sequential step, the formaldehyde containing the extracted agent is preferably removed from the tissue prior to contacting the tissue with a new fraction of formaldehyde.

25 In another preferred embodiment, the aldehyde used in the method of the present invention is glutaraldehyde. In the same fashion as described above, the tissue can be treated with substantially any amount of formaldehyde that provides the sought after results.

In an exemplary embodiment, the application of glutaraldehyde is  
30 similar to that of formaldehyde. The tissue is treated with a solution of glutaraldehyde containing from about 0.2% to about 3% of glutaraldehyde. The extraction can be performed as a single step. Alternatively, the extraction can be performed as a series of sequential steps. At the end of each sequential step, the

glutaraldehyde containing the extracted agent is preferably removed from the tissue prior to contacting the tissue with a new fraction of glutaraldehyde.

Although certain preferred embodiments of the present invention are illustrated by the use of formaldehyde or glutaraldehyde to remove infectious agent binding sites from mammalian tissue, this focus on the use of these two aldehydes is for clarity of illustration and should not be construed as defining or limiting the scope of the invention.

The skilled practitioner will recognize that other agents are suitable for use in the method of the present invention. An exemplary agent of use in the invention is a cross linking agent. A list of cross linking agents can be found in U.S. Patent No. 6,214,054, which is incorporated by reference in its entirety. Yet another exemplary agent is a denaturing agent. Exemplary denaturing agents can be found in U.S. Patent No. 6,214,054, which is incorporated by reference in its entirety.

In a preferred embodiment, the method of the present invention includes contacting the bioprosthetic tissue with a protic solvent, either alone or in combination with another agent disclosed herein or otherwise known to be useful to remove phospholipids from tissue. Protic solvents of use in practicing the present invention include water, alcohols, carboxylic acids, and the like. Although any protic solvent that has desirable characteristics for a particular application can be used to practice the present invention, certain protic solvents are preferred.

In a preferred embodiment, the method of the present invention uses an alcohol or other solvent incorporating an alcohol. The tissue is treated with substantially any amount of alcohol that provides the sought after results. The determination of the correct amount of alcohol needed for a particular application is well within the abilities of those of skill in the art. For example, a tissue is extracted one or more times with alcohol and the extracted material is collected. The amount of infectious material or chemical agent removed by the extraction is determined. When the alcohol ceases to remove infectious agent and/or chemical agent from the tissue an end point is reached, which is indicative of the amount of alcohol necessary to remove the particular agent from the tissue.

In a preferred embodiment utilizing an alcohol, the tissue is treated with an aqueous alcohol solution containing from about 10% to about 100%

alcohol, more preferably from about 20% to about 80% alcohol. The extraction can be performed as a single step. Alternatively, the extraction can be performed as a series of sequential steps. At the end of each sequential step, the alcohol containing the extracted agent is preferably removed from the tissue prior to  
5 contacting the tissue with a new fraction of the alcohol.

Preferred alcohols include one or more compounds of the group consisting of methanol, ethyl alcohol, propyl alcohol, butyl alcohol, pentyl alcohol, hexyl alcohol, heptyl alcohol, octyl alcohol, nonyl alcohol, decyl alcohol, and the like. Although any alcohol that has desirable characteristics for a particular  
10 application can be used to practice the present invention, certain alcohols are preferred.

In yet another preferred embodiment, a method of the present invention uses ethanol.

In a preferred embodiment, the surfactant is from a group including  
15 anionic, cationic, nonionic, and amphoteric surfactants. Although any surfactant that has desirable characteristics for particular application can be used to practice the present invention, certain surfactants are presently preferred.

In another embodiment, the present invention utilizes a surfactant or detergent in the extraction mixture. Any detergent or surfactant known to those of  
20 skill in the art is of use in practicing the present invention.

In a preferred embodiment, the method of the present invention uses a nonionic surfactant as the surfactant. Nonionic surfactants include, without limitation, various ethoxylates, carboxylic acid esters, glycol esters, polyoxyethylene esters, anhydrosorbitol esters, ethoxylated anhydrodrosorbitol  
25 esters, glycerol esters of fatty acids, carboxylic amides, diethanolamine condensates, and the like. Presently preferred nonionic surfactants also include ethoxylated natural fats, oils and waxes.

In a presently preferred embodiment, the ethoxylated natural fats, oils, and waxes are from a group including, without limitation, lauric, oleic, stearic,  
30 and palmitic fatty acids having trade names such as Armotan, Emsorb, Glycosperse, Hodag, and Tween. In a particularly preferred embodiment, the surfactant is Tween 80, an oleic fatty acid.

Of particular interest is a surfactant preparation that can be used to treat tissues that contain or may contain infectious agents, binding sites for these agents and/or calcium nucleation sites. Surfactants of use in the present invention include any surfactant, either substantially pure or containing additives, that  
5 prevents or inhibits infectivity in mammalian tissue.

Surfactants such as Tween 80 have been widely used in biochemical applications including: solubilizing proteins, isolating nuclei from cells in culture, growing of tubercule bacilli, and emulsifying and dispersing substances in medicinal and food products. In part, due to these desirable properties, Tween 80  
10 is a presently preferred surfactant.

In a preferred embodiment utilizing Tween 80, the tissue is treated with a solution containing from about 0.1% to about 10% Tween 80. The extraction can be performed as a single step. Alternatively, the extraction can be performed as a series of sequential steps. At the end of each sequential step, the  
15 Tween 80 containing the extracted agent is preferably removed from the tissue prior to contacting the tissue with a new fraction of Tween 80.

The skilled practitioner will recognize that many other surfactants are suitable for use in the method of the present invention. A list of additional surfactants can be found in U.S. Patent No. 6,214,054, which is incorporated by  
20 reference in its entirety.

In a preferred embodiment, the present invention provides a method for removing essentially all phospholipid in a tissue by contacting the tissue with a combination of formaldehyde, ethanol, and Tween 80. In this embodiment, phospholipid calcium nucleation sites and binding sites for proteins such as prion,  
25 acetylcholinesterase, alkaline phosphatase, and Thy-1, are removed. By removing the calcium nucleation site and/or the binding site for a protein, the actual protein can be more easily removed by simple washing or is itself removed as it remains associated with the binding site. In a related embodiment, other chemical combinations able to extract phospholipid serve an equivalent function.

30 As discussed above, phospholipids have been implicated as binding sites for prions, infectious agents, calcium and other undesirable substances. A wide variety of phospholipases are known to degrade phospholipids. Thus, in a further embodiment, the method of the present invention removes a binding or

nucleation site from bioprosthetic tissue by contacting the tissue with a preparation including a phospholipase.

The skilled practitioner will appreciate that there are several methods for analyzing the aforementioned phospholipid removal techniques. The tissue can be treated with substantially any amount of phospholipid removing agent that provides the sought after results. The determination of the correct amount of agent is well within the abilities of those of skill in the art. A particularly preferred approach for phospholipid analysis is set out below, in the Examples section.

In yet another preferred embodiment, the method of the present invention further includes one or more steps selected from the group including fixation, bioburden reduction, final sterilization, and packaging. The removal step is performed either before, during, or after fixation. In another related embodiment, the removal step is performed during bioburden reduction, sterilization, or packaging. In yet another related embodiment, the method of the present invention includes the removal of the binding site for endogenous prion protein.

In another preferred embodiment, the method also includes a washing step. In still another preferred embodiment, the method includes a terminal sterilization step, such as that described in U.S. Patent No. 6,214,054.

In yet another preferred embodiment, the structural integrity of the tissue is maintained. Structural integrity can be defined as the ability of tissue to perform its necessary biological function. The artisan will appreciate that the degree of structural integrity required for the tissue to perform its necessary function may vary among different types of tissues. Further, particular applications for which the tissue is used may require different levels of structural integrity.

In a related embodiment, the present invention provides a method for predicting the amount of post implant calcification that will occur in a fixed bioprosthetic tissue. An exemplary method includes assaying the amount of phospholipid in the bioprosthetic tissue and comparing the amount of phospholipid with a standard curve correlating amount of phospholipid with amount of post implant calcification for the tissue. Methods of correlating amount of phospholipid

with amount of post implant calcification are set forth in the Examples appended hereto.

Also provided is a method for optimizing a process by which bioprosthetic tissues are prepared. The method includes assessing the amount of post implant calcification of bioprosthetic tissues prepared by different methods. In an exemplary embodiment, the process that produces a bioprosthetic tissue that undergoes the minimum post implantation calcification serves as an end point for the optimization.

In a related embodiment, quality control of bioprosthetic tissue can be maintained by the steps of selecting the maximum amount of post implantation calcification for a bioprosthetic tissue. The potential for post implantation calcification of the bioprosthetic tissue is determined by a method such as that set forth in the examples, and the determined calcification is compared to the maximum amount of post implantation calcification.

#### **Removing Binding Sites - Protein or Polysaccharide Components**

In a second aspect, the present invention provides a method for eliminating or reducing infectivity in a biological material. A related embodiment provides a method for eliminating or reducing infection, including prion infection, in a bioprosthetic tissue. The method includes removing a binding site contained in the tissue so that an infectious agent is prevented or inhibited from binding to the tissue. Typically, the invention is applicable to combating a wide variety of infectious agents, and for preventing their transmission during implantation of a tissue graft. A related embodiment provides a method for removing a protein or polysaccharide component of the binding site to which an infectious agent, including prion protein, can bind. In a further related embodiment, the present invention provides for the removal of a binding site having both a protein and a polysaccharide component, e.g., a proteoglycan.

The invention is also applicable to combating viruses of the family of Picornaviridae, in particular of the genus Hepatovirus, such as the Hepatitis A virus, and for preventing their transmission during tissue grafts. In a this embodiment, the method of the present invention includes removing from a tissue a binding site for the Hepatitis A virus.

Viruses have been implicated in various diseases, including liver disease. In U.S. Patent No. 5,622,861, Kaplan *et al.* discuss the Hepatitis A virus, and in particular the isolation of a cellular receptor that is thought to recognize the Hepatitis A virus. Specifically, it is suggested that Hepatitis A virus binds to a 451 amino acid protein. In a preferred embodiment, the present invention provides a method for removing a protein component of a binding site for the Hepatitis A virus.

Subsequent publications by Kaplan and others have further characterized a protein binding domain for the Hepatitis A virus, and a defined amino acid profile has emerged. *See, e.g.,* Thompson *et al.*, "The Cys-Rich Region of Hepatitis A Virus Cellular Receptor 1 is Required for Binding of Hepatitis A Virus and Protective Monoclonal Antibody 190/4," *J. Virol.*, **72**(5): 3751-3761 (1998), Feigelstock *et al.*, "Polymorphisms of the Hepatitis A Virus Cellular Receptor 1 in African Green Monkey Kidney Cells Result in Antigenic Variants That Do No React with Protective Monoclonal Antibody 190/4," *J. Virol.*, **72**(7):6218-6222 (1998), and Silberstein *et al.*, "Neutralization of Hepatitis A Virus (HAV) by an Immunoadhesion Containing the Cysteine-Rich Region of HAV Cellular Receptor-1," *J. Virol.*, **75**(2):717-725 (2001).

In addition to proteins, polysaccharides have been widely implicated as infectious agent binding sites. Infectious agents such as the Sindbis virus, Vaccinia Virus, Classical Swine Fever Virus, Human papillomavirus, Human herpesvirus, Echovirus, Foot and Mouth Disease Virus, and Respiratory Syncytial Virus are believed to recognize a binding site that includes polysaccharide. *See, for example,* Byrnes *et al.*, "Binding of Sindbis Virus to Cell Surface Heparan Sulfate," *J. Virol.* **72**(9):7349-7356 (1998); Hsiao *et al.*, "Vaccinia Virus Envelope D8L Protein Binds to Cell Surface Chondroitin Sulfate and Mediates the Adsorption of Intracellular Mature Virions to Cells," *J. Virol.* **73**(10):8750-8761 (1999); Giroglou *et al.*, "Human Papillomavirus Infection Requires Cell Surface Heparan Sulfate," *J. Virol.* **75**(3):1565-1570 (2001); and Goodfellow *et al.*, "Echoviruses Bind Heparan Sulfate at the Cell Surface," *J. Virol.* **75**(10):4918-4921 (2001). Polysaccharides are also believed to serve as a binding site for toxigenic molecules. *See, e.g.,* Utt *et al.*, "Helicobacter Pylori Vacuolating Cytotoxin Binding to a Putative Cell Surface Receptor, Heparan

Sulfate, Studied by Surface Plasmon Resonance,” *FEMS Immunol. Med. Microbiol.* **30**(2):109-113 (2001).

In a preferred embodiment, the present invention provides a method for removing a binding site from bioprosthetic tissue wherein the binding site includes polysaccharide. Exemplary polysaccharides include, but are not limited to, branched polysaccharides, unbranched polysaccharides, mucopolysaccharides, heteropolysaccharides, and glycosaminoglycans. In a presently preferred embodiment, the method provides for removal of a binding site from the bioprosthetic tissue, where the binding site includes a glycosaminoglycan selected from the group including, without limitation, hyaluronic acid, chondroitin sulfate (A, B, or C), dermatan sulfate, heparan sulfate, heparin (both high and low molecular weight heparin), and keratan sulfate.

Proteoglycans are also known to occur in infectious agent binding sites. Infectious agents such as *Orientia tsutsugamushi*, human immunodeficiency virus, *Neisseria gonorrhoeae*, visna virus, and dengue virus are believed to recognize a binding site that includes proteoglycan. See, for example, Ihn *et al.*, “Cellular Invasion of *Orientia Tsutsugamushi* Requires Initial Interaction with Cell Surface Heparan Sulfate,” *Microb. Pathog.* **28**(4):227-233 (2000); Valenzuela-Fernandez *et al.*, “Optimal Inhibition of X4 Isolates by the CXCL12 Chemokine SDF-1α Requires Interaction with Cell-Surface Heparan Sulfate Proteoglycan,” *J. Biol. Chem.* May 14, 2001 Pubmed epub; Grant *et al.*, “Proteoglycan Receptor Binding by *Neisseria Gonorrhoeae* MS11 is Determined by the HV-1 Region of OpaA,” *Mol. Microbiol.* **32**(2): 233-242 (1999); and Hilgard *et al.*, “Heparan Sulfate Proteoglycans Initiate Dengue Virus Infection of Hepatocytes,” *Hepatology* **32**(5): 1069-1077 (2000).

In a preferred embodiment, the present invention provides a method for removing a binding site from bioprosthetic tissue wherein the binding site includes proteoglycan. Proteoglycan typically includes a protein core, to which glycosaminoglycan is attached. In this embodiment, exemplary proteoglycans include, but are not limited to, heparan sulfate proteoglycan and chondroitin. Further exemplary proteoglycans will include any of the aforementioned glycosaminoglycans, as well as other glycoproteins that act as a binding site.

Additionally, integrins are known to occur in infectious agent binding sites. Infectious agents such as adenovirus, foot and mouth disease virus, and *Streptococcus pyogenes* are believed to recognize a binding site that includes integrin. See, for example, Li *et al.*, "Integrin Alpha(v)beta(1) is an Adenovirus Coreceptor," *J. Virol.* **75**(11):5405-5409 (2001); Miller *et al.*, "Role of the Cytoplasmic Domain of the Beta-Subunit of Integrin Alpha(v)beta(6) in Infection by Foot and Mouth Disease Virus," *J. Virol.* **75**(9):4158-4164 (2001); and Molinari *et al.*, "Two Distinct Pathways for the Invasion of *Streptococcus pyogenes* in Non-Phagocytic Cells," *Cell Microbiol.* **2**(2): 145-154.

In a preferred embodiment, the present invention provides a method for removing a binding site from bioprosthetic tissue where the binding site includes integrin. Integrins typically occur as heterodimers, and include an alpha and a beta subunit. Exemplary integrins include, but are not limited to, alpha(V)beta(1), alpha(6)beta(1), and alpha(L)beta(2). Further exemplary integrins include any heterodimer combination including an alpha integrin subunit, such as alpha(1), alpha(2), alpha(3), alpha(5), alpha(6), alpha(7), alpha(8), alpha(L), alpha(M), alpha(X), alpha(IIB), alpha(V), or alpha(IEL) and a beta subunit, such as beta(1), beta(2), beta(3), or beta(4).

In a further preferred embodiment, the method of the present invention removes a PrP protein binding site from a bioprosthetic tissue. In a particularly preferred embodiment, the binding site may include, without limitation, heparin, heparan sulfate binding protein, integrin, and other cationic domains typically found on cell surfaces or in tissue extracellular matrix. In a related embodiment, the method of the present invention includes contacting the tissue with an enzyme to effect the removal of the binding site. The present invention contemplates that the prion binding site may also include any of the polysaccharides, proteoglycans, or integrins discussed above. In a particularly preferred embodiment, the method uses the enzyme heparinase to digest heparin and thus remove this binding site for the prion protein.

In another preferred embodiment, the method of the present invention removes the PrP binding site by contacting the tissue with a chemical solution that dissociates or extracts the PrP binding site. In a particularly preferred embodiment, the tissue is contacted with a chemical selected from the group

including solvents, surfactants, and chaotropic agents. In another preferred embodiment, a polycationic binding site is chemically derivatized, thereby effectively eliminating the binding site for the PrP protein. The artisan will appreciate that the tissue may be contacted with the solution or agent for a period  
5 of time sufficient to affect the removal, extraction, or derivatization of the binding site. The present invention further contemplates that this process may optionally include heating, stirring/fluid movement, or both.

The tissue can be treated with substantially any amount of chemical or enzyme solution that provides the sought after results. The determination of the  
10 correct amount of chemical or enzyme solution is well within the abilities of those of skill in the art. For example, a tissue is extracted one or more times with the solution, and the amount of specific protein or polysaccharide remaining in the tissue is analyzed. When the amount of remaining protein or polysaccharide ceases to change, an end point is reached, which is indicative of the amount of  
15 solution necessary to remove the particular protein or polysaccharide from the bioprosthetic tissue.

In yet another preferred embodiment, the method of the present invention further includes one or more step selected from the group including fixation, bioburden reduction, final sterilization, and packaging. In a related  
20 embodiment, the removal step is performed either before, during, or after fixation. In another related embodiment, the removal step is performed during bioburden reduction, sterilization, or packaging. In yet another related embodiment, the method of the present invention includes the removal of binding sites for endogenous prion protein.

25

### **Blocking Binding Sites**

In a third aspect, the present invention provides a method for blocking a binding site for an infectious agent or a calcium nucleation site, which is contained in a bioprosthetic tissue. The method includes contacting the tissue  
30 with a preparation including a sulfated polyanion, thereby blocking the calcium nucleation or infectious agent binding site. Alternatively, the method includes contacting the tissue with a preparation including a lipopolyamine, thereby blocking the calcium nucleation or infectious agent binding site.

During the course of pathogenesis, the infectious agent or toxigenic substance will typically bind to a host cell surface receptor, thereby initiating damage to the cell. In a preferred embodiment, the present invention provides methods for blocking a cell surface receptor, so that these harmful substances are prevented or inhibited from binding to the host cell. Lipoteichoic acid, for example, is produced by the gram positive organism *Staphylococcus aureus*, and has been strongly implicated in sepsis, a deadly disease. See, for instance, Kengatharan *et al.*, "Mechanism of Gram-Positive Shock: Identification of Peptidoglycan and Lipoteichoic Acid Moieties Essential in the Induction of Nitric Oxide Synthase, Shock, and Multiple Organ Failure," *J. Exp. Med.* **188**(2):305-315 (1998). The cell surface receptor for lipoteichoic acid also exhibits binding specificity for polyanions such as heparin. See, for example, Dziarski *et al.*, "Heparin, Sulfated Heparinoids, and Lipoteichoic Acids Bind to the 70-kDa Peptidoglycan/Lipopolysaccharide Receptor Protein on Lymphocytes," *J. Biol. Chem.* **269**(3):2100-2110 (1994).

In a preferred embodiment, the present invention provides a method for blocking a calcium nucleation and/or an infectious agent binding site in a bioprosthetic tissue by contacting the tissue with a preparation including a sulfonated polyanion. In a preferred embodiment, the sulfonated polyanion is selected from the group including, without limitation, sulfated polysaccharides, polyvinyl sulfate, polyanethole sulfonate, carrageenan, pentosan polysulfate, sulfated colomycin, heparin, heparan sulfate, fucoidan, sulfated cyclodextrins, dextran sulfate, chondroitin sulfate, keratan sulfate, hyaluronic acid, any of the glycosaminoglycans described above, and synthetic variants and analogs thereof. In another embodiment, the preparation includes a lipopolyamine, such as the cationic lipopolyamine DOSPA.

Similarly, sulfated polyanions are known to compete with prion protein by binding to cell surface receptors such as heparan sulfate binding protein, integrins, and other binding domains on cells. When sulfated polyanions are given in cell culture or animal models, for example, binding of prion protein to the cell is prevented and development of spongiform disease symptoms is blocked. Thus, in a related embodiment, the infectious agent is a prion protein. In a further related embodiment, the binding site is a cell surface receptor from the group including,

without limitation, heparan sulfate binding protein, integrins, and other binding domains on cells. In another related embodiment, the present invention provides a method for blocking a prion protein binding site in a bioprosthetic tissue by contacting the tissue with a preparation including a sulfated polyanion.

5                   In a related embodiment, the method further includes washing the tissue with repeated washes of a sulfated polyanion, such as a polysulfonated polyglycoside, which competes with the infectious agent for the binding site in the tissue. If washing conditions are sufficient (i.e. compound type and amount, washing conditions and temperature) the washing agent will effectively replace the  
10                   infectious agent on the binding sites and the PrP can be washed away. Elevated temperatures, such as 37° C may be desirable in the washing step to promote dissociation-reassociation phenomena and to increase the efficiency of removal of the infectious agent.

                  The tissue can be treated with substantially any amount of sulfated  
15                   polyanion that provides the sought after results. The determination of the correct amount of sulfated polyanion needed for a particular application is well within the abilities of those of skill in the art. For example, a tissue is contacted one or more times with sulfated polyanion, and the tissue is then analyzed to determine if additional sulfated polyanion may bind to the tissue. When no more additional  
20                   sulfated polyanion may bind to the tissue, an end point is reached, which is indicative of the amount of sulfated polyanion necessary to block the particular agent from the tissue. In addition, tissue may be stored in the presence of polyanion in order to ensure saturation of the binding site prior to use.

## 25                   **Removing or Blocking Infectious Agents**

                  In a fourth aspect, the present invention also provides a method for removing or blocking an infectious agent. A related embodiment provides a method for removing or blocking an infectious agent in a biological material. In a particularly preferred embodiment, the method includes contacting the tissue with  
30                   a substance that binds to the infectious agent. In a further related embodiment, the contacting step may be followed by a washing step.

                  One of skill in the art will appreciate that the methods of the present invention are well suited for disinfecting or sterilizing a variety of medical

instruments or work surfaces. In a preferred embodiment, the present invention includes contacting a medical instrument or a work surface with a substance that binds to the infectious agent, for example, by dipping the instrument in a solution containing the binding substance. This approach may be used to treat pre-existing  
5 contamination in an instrument or work surface, and may optionally include a washing step. In a related embodiment, an instrument may be stored in a solution that contains a substance that binds to the infectious agent, thereby preventing or inhibiting contamination of the instrument.

The methods of the present invention may also be used for  
10 decontaminating or otherwise treating containers intended for holding or storing biological tissues or medical instruments.

A wide variety of substances are known to bind to infectious agents. Frequently, these substances are investigated as potential therapeutics against infectious agents such as *Chlamydia trachomatis*, herpes simplex virus,  
15 cytomegalovirus, HIV, Malarial sporozoites, and the like. See, for example, Zaretzky *et al.*, "Sulfated Polyanions Block *Chlamydia Trachomatis* Infection of Cervix-Derived Human Epithelia," *Infect. Immun.* **63**(9):3520-3526 (1995); Witvrouw *et al.*, "Sulfated Polysaccharides Extracted from Sea Algae as Potential Antiviral Drugs," *Gen. Pharmacol.* **29**(4):497-511 (1997); Gonzalez *et al.*,  
20 "Polysaccharides as Antiviral Agents: Antiviral Activity of Carrageenans," *Antimicrob. Agents Chemother.* **31**(9):1388-1393 (1987); Gotoh *et al.*, "Sulfated Fibroin, a Novel Sulfated Peptide Derived from Silk, Inhibits Human Immunodeficiency Virus Replication in Vitro," *Biosci. Biotechnol. Biochem.* **64**(8):1664-1670 (2000); and Herold *et al.*, "Sulfated Carbohydrate Compounds  
25 Prevent Microbial Adherence by Sexually Transmitted Disease Pathogens," *Antimicrob. Agents Chemother.* **41**(12):2776-2780 (1997).

In a preferred embodiment, the present invention provides a method for blocking an infectious agent from a bioprosthetic tissue by contacting the tissue with a substance that binds to the infectious agent. In a related embodiment, the  
30 present invention provides a method for removing an infectious agent from a bioprosthetic tissue by contacting the tissue with a substance that binds to the infectious agent, and thereafter washing the tissue.

Among the myriad infectious agents, prion proteins are of significant interest. Thus, also of interest are substances that bind to prion protein. Among these are sulfated polyanions such as Congo red, heparin, pentosan polysulfate, chondroitin sulfate, and dextran sulfate. *See, for example, Caughey et al.*, “Binding of the Protease-Sensitive Form of Prion Protein PrP to Sulfated Glycosaminoglycan and Congo Red,” *J. Virol.* **68**(4): 2135-2141 (1994); Ehlers *et al.*, “Dextran Sulphate 500 Delays and Presents Mouse Scrapie by Impairment of Agent Replication in Spleen,” *J. Gen. Virol.* **65**: 1325-1330 (1984); Demaimay *et al.*, “Inhibition of Formation of Protease-Resistant Prion Protein by Trypan Blue, Sirius Red and Other Congo Red Analogs,” *Arch. Virol. Suppl.* **16**: 277-283 (2000); Mangé *et al.*, “Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures,” *J. Virol.* **74**(7): 3135-3140 (2000); Caughey, “Scrapie-Associated PrP Accumulation and Agent Replication: Effects of Sulphated Glycosaminoglycan Analogues,” *Philos. Trans. R. Soc. Lond B. Biol. Sci.* **343**(1306): 399-404 (1994); Priola *et al.*, “Porphyrin and Phthalocyanine Antiscrapie Compounds,” *Science* **287**: 1503-1506 (2000); and Tagliavini *et al.*, “Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters,” *Science* **276**: 1119-1122 (1997).

The etiology of prion disease is unique, and is believed to involve a recruitment process whereby the infectious form of the prion protein facilitates the conversion of normal prion into that of infectious prion. Due to this remarkable mechanism, the infectious agent blocking substance used in the present invention includes any substance that blocks the prion protein in its infectious form, thereby inhibiting or eliminating the ability of the infectious form to further transform non-infectious prion into the infectious form. Equally as important, the infectious agent blocking substance will also include any substance which blocks the prion protein in its non-infectious prion, and hinders or otherwise prevents the transformation of the non-infectious prion into the infectious form.

In a particularly preferred embodiment, the present invention provides a method for blocking an infectious agent in a bioprosthetic tissue by contacting the tissue with preparation including polysaccharide. Exemplary polysaccharides include, but are not limited to, branched polysaccharide, unbranched polysaccharide, mucopolysaccharide, heteropolysaccharide, and

glycosaminoglycan. In a presently preferred embodiment, the preparation includes a glycosaminoglycan selected from the group including, without limitation, hyaluronic acid, chondroitin sulfate (A, B, or C), dermatan sulfate, heparan sulfate, pentosan polysulfate, heparin (both high and low molecular weight heparin),  
5 keratan sulfate, and glycosaminoglycan analogs. The artisan will appreciate that glycosaminoglycan will also include synthetic variants and analogs thereof. For example, Congo Red is a recognized glycosaminoglycan analog. Accordingly, the preparation may include Trypan Blue, Sirius Red F3B, Evans Blue, Fast Red, Trypan Red, Primuline, Thioflavin-S, or the like.

10 In a further preferred embodiment, the method includes contacting the tissue with a preparation including heteropolyanion, polyene antibiotic, polyanion, sulfated polyanion, sulfated cyclodextrin, carrageenan, and sulfated polysaccharide.

In another preferred embodiment, the present invention provides a  
15 method for blocking an infectious agent in a bioprosthetic tissue by contacting the tissue with a preparation including an antifungal agent. In a related embodiment, the preparation includes a polyene antibiotic, such as Amphotericin B. Further, the preparation may include a polyanionic antifungal agent, or other compounds used to treat or diagnose amyloid disease.

20 In a preferred embodiment, the preparation includes a porphoryin or a phthalocyanine. Exemplary compounds of this type include PcTS (phthalocyanine tetrasulfonate), TMPP-Fe<sup>3+</sup> [meso-tetra(4-N-methylpyridyl)porphine iron (III)], DPG2-Fe<sup>3+</sup> [deuteroporphyrin IX 2,4-bis-ethylene glycol) iron(III)], or other tetrasubstituted porphoryin.

25 In a further embodiment, the present invention provides a method for blocking an infectious agent in a bioprosthetic tissue by contacting the tissue with a preparation including an anthracycline, such as 4'-iodo-4'-deoxy-doxorubicin. In another embodiment, the method involves contacting a tissue with a preparation including sulfated fibroin, a peptide derived from silk. Optionally,  
30 the method may contacting a tissue with a preparation including a sulfated carbohydrate, or a sulfated maltoheptaose derivative, such as N-acetyl-β-maltoheptaosylamine sulfate.

In an alternate embodiment, the present invention provides a method for blocking an infectious agent in a bioprosthetic tissue by contacting the tissue with a preparation including synthetic sulfated polymer, such as a copolymer of acrylic acid with vinyl alcohol sulfate (PAVAS). In another embodiment, the preparation includes a sulfated chaotropic surfactant, such as sodium laurel sulfate.

In another preferred embodiment, the present invention provides a method for blocking an infectious agent in a bioprosthetic tissue by contacting the tissue with a preparation including a branched polyamine. Exemplary branched polyamines include, without limitation, polyamidoamine and polypropyleneimine (PPI) dendrimers, polyamidoamide dendrimers, and polyethyleneimine. In a related embodiment, the preparation includes branched polyamine and chloroquine.

In a presently preferred embodiment, the present invention provides a method for blocking an infectious agent in a bioprosthetic tissue by contacting the tissue with a preparation including a lysosomotropic agent or a cysteine protease inhibitor. Exemplary lysosomotropic agents include, without limitation, quinacrine, tilorone, chloroquine, and suramine. Exemplary cysteine protease inhibitors include, without limitation, E-64d, E-64, and leupeptin.

In another preferred embodiment, the present invention provides a method for blocking an infectious agent in a bioprosthetic tissue by contacting the tissue with a preparation including a denaturing agent such as glutaraldehyde. While no theoretical explanation can be given with certainty for the blocking effect of this denaturing agent, it is believed that it prevents infectious prion replication by stabilizing the non-infectious form of the prion protein, and in particular by modifying the lysine residues at positions 184 and 193 of the prion. The artisan will recognize that other substances that similarly modify these lysine residues, or otherwise stabilize the non-infectious form of the prion protein, are well suited for use in the method of the present invention.

In yet another preferred embodiment, the present invention provides a method for blocking an infectious agent in a bioprosthetic tissue by contacting the tissue with a beta-sheet blocker, or a beta sheet breaker peptide, such as iPrP13. This approach is based on the concept that the secondary structure of the infectious

form of the prion protein presents beta sheet conformation, whereas the non-infectious form contains alpha helix.

While the above embodiments envisage blocking the infectious agent, it is also apparent that by contacting the tissue with copious amounts of the substance that binds to the infectious agent, bioprosthetic tissue can be rendered free of some or all contamination.

The artisan will appreciate that these binding substances may be used to bind either to exogenous prion protein, or to endogenous prion protein. Similarly, the binding substances may be used to disinfect contaminated or infected tissue, or to prohibit tissue from becoming contaminated or infected. In a preferred embodiment, the tissue is perfused with a preparation including a binding substance, thereby blocking any prion infectivity. In a related preferred embodiment, the present invention provides a method for preventing or inhibiting infectivity in a bioprosthetic tissue by contacting the tissue with one or more of the above mentioned binding substances, and extracting and washing away the bound complex of binding substance and prion. In these embodiments, any possible conversion of  $\text{PrP}^{\text{C}}$  to the mutant form,  $\text{PrP}^{\text{Sc}}$  is prevented or inhibited.

The tissue can be treated with substantially any amount of infectious agent blocking substance that provides the sought after results. The determination of the correct amount of blocking substance is well within the abilities of those of skill in the art. For example, a tissue is extracted one or more times with the blocking substance, and the amount of infectious agent remaining in the tissue is analyzed. When the amount of remaining infectious agent ceases to change, an end point is reached, which is indicative of the amount of substance necessary to block the particular infectious agent from the bioprosthetic tissue.

The materials, methods and devices of the present invention are further illustrated by the examples that follow. These examples are offered to illustrate, but not to limit the claimed invention.

## EXAMPLES

### EXAMPLE 1

#### 1.1 Phospholipid Removal

Several lots of fresh pericardial tissue were obtained from two different vendors. The samples were subjected to the following protocol: (1) a first fixation step, (2) a second fixation step, (3) a first bioburden reduction process, (4) a second bioburden reduction process, and (5) a terminal liquidation sterilization process.

#### 1.2 Phospholipid Analysis

Studies were performed to objectively assess the efficacy of the above-described method in removing phospholipid from tissue. The samples were smashed, lyophilized, weighed, rehydrated with water, and extracted with a mixture including chloroform, methanol, and BHT. Saline was added to the mixture, and the sample was centrifuged. The lower phase of chloroform was collected and dried under nitrogen gas, and then reconstituted with a mixture of chloroform and BHT.

The samples were then spotted on a thin layer chromatography (TLC) plate with mixed phospholipid standards. The plates were dried, stained, and scanned to measure the density of fluorescence spots. The final results were converted from  $\mu\text{g}$  phospholipid in the spot to  $\mu\text{g}/\text{mg}$  dry weight tissue.

#### 1.3 Results

The following phospholipid levels were observed following each step of the protocol.

| Protocol Step                      | Average Percent Removal | Total Phospholipid<br>$\bar{X} \pm SD$ | Range            |
|------------------------------------|-------------------------|----------------------------------------|------------------|
| Fresh sample                       | (N/A)                   | $7.244 \pm 3.055$                      | (2.180 - 12.469) |
| First fixation step                | (46%)                   | $3.884 \pm 1.612$                      | (1.887 - 7.552)  |
| Second fixation step               | (34%)                   | $4.775 \pm 1.326$                      | (2.929 - 7.722)  |
| First bioburden reduction          | (76%)                   | $0.553 \pm 0.225$                      | (0.248 - 0.983)  |
| Second bioburden reduction         | (98%)                   | $0.132 \pm 0.057$                      | (0.061 - 0.302)  |
| Terminal liquidation sterilization | (98%)                   | $0.120 \pm 0.084$                      | (0.026 - 0.326)  |

The percentage of phospholipid (PL) removal was determined as follows.

$$\% \text{ PL Removal} = \frac{\text{Total PL Fresh Tissue} - \text{Total PL Processed Tissue}}{\text{Total PL Fresh Tissue}}$$

5

As illustrated by the formula, the percentage of phospholipid removal was calculated in comparison to fresh tissue.

## EXAMPLE 2

### 10 2.1 Materials and Methods

Forty-eight commercial bioprosthetic valves of eight different types were obtained from suppliers. Six Carpentier-Edwards Duraflex, three SAV, and six PERIMOUNT valves were obtained from Edwards Lifesciences. Seven Mosaic, nine Freestyle and eight Hancock II valves were obtained from Medtronic. 15 Eight Toronto SPY valves were obtained from St. Jude Medical. One Mitroflow Model 12 valve was obtained from Sulzer Carbomedics. Control pericardial tissues were prepared by fixation and storage in 0.625% w/v glutaraldehyde solution only. Fresh porcine leaflet and pericardial tissues were tested 'as received' from approved slaughterhouses and represented commercial-quality 20 tissue. Tissue samples were excised using aseptic technique and tested as outlined below.

### 2.2 Tissue Characterization

#### 2.2(a) Methods

#### 25 2.2(a1) Shrinkage temperature

Porcine leaflet and pericardial tissue strips measuring 5 mm x 15 mm were excised and loaded into the fixture. The fixture was lowered into a bath and the solution was heated at 0.8°C per minute while a strain gauge measured the strain in the tissue. The shrinkage temperature was taken as the temperature at 30 which the tissue length shrank by 1%.

*2.2(a2) Moisture content*

Porcine leaflet and pericardial tissues were weighed, then lyophilized to dryness and reweighed to calculate moisture content.

5 *2.2(a3) Free amine content*

Porcine leaflet and pericardial tissues were analyzed using a modification of the ninhydrin method. Briefly, tissues were incubated with a colorimetric reagent which reacts with free  $\alpha$ -amities to form a purple complex. The complex was detected using standard spectroscopy methods and quantitated  
10 using a standard curve of N- $\alpha$ -acetyl lysine. Values are reported as nmol free amine per mg dry tissue weight.

*2.2(b) Results*

Table 1 contains the overall average and standard deviation for each  
15 of the valve types for shrinkage temperature, moisture content, and free amine content. These results indicate all valves tested were well-crosslinked, yielding values typical of glutaraldehyde-treated tissues. Only moisture content differed significantly amongst the valves, where the moisture content of the porcine leaflet tissues was about 92% and the bovine pericardium was about 79%. This  
20 difference reflects differences in the tissues rather than any effects of processing.

Table 1. Shrinkage temperature, Moisture content, Free Amine Content for Valve Tissues:

| Valve Type:           | Shrinkage Temperature:<br>(°C) |              | Moisture Content:<br>(%) |              | Free Amine Content:<br>(nmol/mg dry weight) |                |
|-----------------------|--------------------------------|--------------|--------------------------|--------------|---------------------------------------------|----------------|
|                       | No. samples                    | Mean +/- SD  | No. samples              | Mean +/- SD  | No. samples                                 | Mean +/- SD    |
| CE Duraflex*          | 50                             | 83.6 +/- 0.8 | 50                       | 92.4 +/- 1.1 | 50                                          | 4.0 +/- 0.8    |
| CE PERIMOUNT*         | 50                             | 83.5 +/- 0.5 | 50                       | 79.2 +/- 1.2 | 50                                          | 3.6 +/- 1.8    |
| Freestyle             | 9                              | 85.7 +/- 0.6 | 9                        | 92.4 +/- 0.8 | 9                                           | 6.8 +/- 0.6    |
| Hancock II            | 8                              | 86.5 +/- 1.2 | 9                        | 92.7 +/- 2.0 | 9                                           | 7.3 +/- 0.6    |
| Mosaic                | 7                              | 85.2 +/- 0.6 | 9                        | 91.1 +/- 1.9 | 9                                           | 8.4 +/- 0.3    |
| CE SAV*               | 50                             | 83.2 +/- 1.2 | 50                       | 91.1 +/- 1.6 | 50                                          | 5.0 +/- 0.6    |
| Toronto SPV           | 8                              | 86.5 +/- 1.4 | 9                        | 92.8 +/- 1.0 | 9                                           | 5.2 +/- 0.7    |
| Fresh Porcine Leaflet | 6                              | 62.2 +/- 0.5 | 12                       | 93.8 +/- 0.5 | 6                                           | 238.6 +/- 15.3 |
| Fresh Pericardium     | 6                              | 61.0 +/- 0.8 | 12                       | 77.7 +/- 0.8 | 6                                           | 181.8 +/- 16.9 |

\*Historical process data.

## 5 2.3 Phospholipid content

### 2.3(a) Method

After the above characterization tests were conducted and implant samples were prepared, the remaining tissues were pooled in groups of three to five valves per group and the phospholipids were extracted in chloroform:methanol 2:1 (v:v), separated using thin layer chromatography (TLC) techniques (Dugan EA. *LC/GC North America* 3:126-128 (1985)), detected using primulin dye, and quantitated after scanning the plate using purified phospholipid standards (Avanti Polar Lipids, Alabaster, Alabama). Image analysis techniques (ImageQuant, Molecular Dynamics, Sunnyvale, California) were used to quantitate the levels of sphingomyelin (SM), phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidic acid (PA). The average value from duplicate runs was used for each sample. These results were then summed to provide a total quantity of phospholipids for each valve type. Phospholipid levels are reported as microgram phospholipid/milligram dry tissue weight.

### 2.3(b) Results

Table 2 lists the phospholipids measured in each valve type.

Because phospholipids are a minor component in tissue (<3% in porcine leaflet and <1% in bovine pericardium) the tissues remaining after conducting the other tests had to be pooled into only two samples per valve type. The average of these two pooled samples is reported in Table 2 and no statistical comparisons are possible.

Table 2. Phospholipid Content of Bioprosthetic Tissues

| Valve Type:           | Phospholipids (µg/mg dry tissue weight) |       |      |      |      |      |       |
|-----------------------|-----------------------------------------|-------|------|------|------|------|-------|
|                       | SM                                      | PC    | PI   | PS   | PE   | PA   | Total |
| CE Duraflex           | 0.55                                    | 1.17  | 0.10 | N/D  | N/D  | 0.06 | 1.88  |
| CE PERIMOUNT          | 0.08                                    | 0.09  | 0.02 | BLQ  | BLQ  | 0.06 | 0.25  |
| Freestyle             | 1.21                                    | 0.55  | 0.16 | BLQ  | 0.29 | 0.22 | 2.44  |
| Hancock II            | 0.66                                    | 0.85  | 0.24 | BLQ  | 0.78 | 0.22 | 2.75  |
| Mitroflow             | 0.86                                    | 0.79  | 0.13 | N/D  | N/D  | N/D  | 1.78  |
| Mosaic                | 0.47                                    | 0.64  | 0.10 | BLQ  | 0.32 | 0.25 | 1.78  |
| CE SAV                | 0.39                                    | 0.16  | 0.18 | N/D  | N/D  | 0.15 | 0.87  |
| Toronto SPV           | 2.19                                    | 4.37  | 0.75 | BLQ  | BLQ  | 0.22 | 7.53  |
| Glut Only Peri        | 1.48                                    | 1.46  | 0.32 | 0.45 | 0.58 | 0.52 | 5.23  |
| Fresh Porcine Leaflet | 4.87                                    | 10.30 | 1.07 | 1.06 | 5.48 | BLQ  | 22.78 |
| Fresh Pericardium     | 1.46                                    | 2.28  | 0.55 | 0.95 | 1.43 | 0.61 | 7.23  |

10 N/D: Not Detectable. Detection Limits 0.1 µg/ul. BLQ: Below Limit of Quantitation (0.2 µg/ul), but detectable.

Sphingomyelin (SM), phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidic acid (PA).

15 Examination of the data in Table 2 reveals marked differences between porcine and pericardial tissues as well as between different processes. Fresh porcine leaflet tissue contains three times more phospholipids compared to fresh bovine pericardial tissues. The distribution of phospholipids also differed between porcine leaflet tissues and bovine pericardium. Finally, fresh pericardium contains phosphatidic acid (PA) while porcine leaflet tissues do not.

20 All commercial processes reduced the phospholipid levels in the tissues compared to fresh tissue, with the lowest value of total phospholipids contained in the CE PERIMOUNT tissue (0.25 µg/mg) and the highest level of

phospholipids found in the Toronto SPV leaflet tissue (7.53 µg/mg). Amongst the porcine leaflet tissues, The CE SAY, Mosaic, and CE Duraflex valves had the lowest phospholipid levels (0.87, 1.78, and 1.88 µg/mg, respectively). The Freestyle and Hancock II leaflets had somewhat higher levels of phospholipids (2.44 and 2.75 µg/mg, respectively) and the Toronto SPV leaflets had the highest levels of phospholipids. Amongst the two pericardial valves tested, the Mitroflow tissue had higher levels of total phospholipids compared to the CE PERIMOUNT (1.78 and 0.25 µg/mg, respectively).

### 10 **EXAMPLE 3**

#### *3.1 Calcification assay*

##### *3.1(a) Rat subcutaneous implantation*

All implantation studies were conducted in compliance with the National Institutes of Health "Guide for the Care and Use of Laboratory Animals". Eight millimeter disks prepared aseptically were rinsed according to manufacturer's recommendations and implanted into the subcutaneous pocket of male Sprague Dawley rats, 21-28 days old, for ninety days. A total of 262 implants were conducted.

##### 20 *3.1(b) Calcium content*

Samples were retrieved and analyzed for calcium content using standard atomic absorption spectroscopy (AAS) methods. Briefly, disks were removed from host tissue, x-rayed, then hydrolyzed in 70% nitric acid. Samples were analyzed using a Varian 200 AAS Spectrometer (Varian Instruments, Walnut Creek, California) and quantitated using calcium standards. Results are reported as microgram calcium/milligram dry tissue weight. The nonparametric Mann-Whitney U - Wilcoxon Rank Sum W Test was used to determine any significant differences between valve types. The relationship between phospholipid levels and calcium content was also examined using nonparametric methods (Spearman's correlation).

### 3.1(c) Histology

Representative samples were taken from each valve type while still contained in host tissue and processed using paraffin embedding techniques. Slides were stained with hematoxylin and eosin, trichrome, and von Kossa stains.

- 5 In each specimen, both the implant tissue and the surrounding host tissue were evaluated and scored for signs of inflammation (acute, chronic, and granulomatous), granulation tissue, scar tissue, hemorrhage, and calcium. The implanted tissues were also examined for signs of collagen degeneration. In all cases, a 0 to +3 system was used. Unimplanted tissues were also evaluated.
- 10 Mitroflow tissue was not examined using this technique.

### 3.2 Results

- Upon explantation, some samples were found folded while others were not. In this study, tissues that were found folded were associated with higher
- 15 calcification levels (data not shown). Therefore the results from the 68 folded samples were excluded from the statistical analysis.

#### 3.2(a) Calcium Content

- Table 3 contains the calcium data from the 194 nonfolded implants
- 20 for each valve type tested. The tissues with the lowest calcium levels were CE SAV, CE Duraflex, and CE PERIMOUNT (0.8, 2.1, and 3.3  $\mu\text{g}$  calcium/mg dry tissue weight, respectively). Tissues with an intermediate level of calcium were the Hancock II, Freestyle, and Mosaic leaflets (8.2, 9.5, and 25.4  $\mu\text{g}$  calcium/mg dry tissue weight, respectively). Tissues with the highest levels of calcium were
- 25 the Mitroflow, Toronto SPV, and the glut-only control (215, 244, and 259  $\mu\text{g}$  calcium/mg dry tissue weight, respectively).

Table 3. Calcium Content of Bioprosthetic Heart Valve Tissues.

|                                                              | CE Duraflex | CE PERI-MOUNT | Freestyle    | Hancock II   | Mitroflow      | Mosaic        | CE SAV      | Toronto SPV    | Glut-only Peri |
|--------------------------------------------------------------|-------------|---------------|--------------|--------------|----------------|---------------|-------------|----------------|----------------|
| No. Valves                                                   | 6           | 6             | 9            | 8            | 1              | 7             | 3           | 8              | N/A            |
| No. Implants                                                 | 32          | 35            | 30           | 16           | 6              | 20            | 20          | 24             | 11             |
| Calcium Content, mean (SD) ( $\mu\text{g}/\text{mg}$ dry wt) | 2.13 (5.99) | 3.30 (8.40)   | 9.54 (36.06) | 8.24 (28.75) | 214.60 (11.44) | 25.37 (57.68) | 0.76 (0.91) | 244.43 (55.69) | 259.26 (41.74) |
| Calcium content, range ( $\mu\text{g}/\text{mg}$ dry wt)     | 30.86       | 35.45         | 187.49       | 115.69       | 35.39          | 204.61        | 4.161       | 289.92         | 160.06         |

N/A = not applicable

Note that not only is the average calcium content of interest, but the variability in the calcium content for each valve type also provides useful information. Table 3 also contains the range measured for each valve type, calculated as the maximum value minus the minimum value. Note the greatest ranges were seen in the Toronto SPV, Mosaic, Freestyle, and Hancock II tissues (all  $>100 \mu\text{g}$  calcium/mg dry wt). Mitroflow, CE PERIMOUNT, CE Duraflex, and CE Cunanan SAV all had smaller ranges, less than  $50 \mu\text{g}$  calcium/mg dry wt.

Table 4 contains the p-values for the comparisons between each of the valve types. In the rat subcutaneous model, CE Duraflex, CE PERIMOUNT, and CE SAV all calcified significantly less than Mosaic, Mitroflow, and Toronto SPV and are not significantly different than Hancock II. In this study, Freestyle tended to calcify more than CE Duraflex and CE PERIMOUNT, although this did not reach statistical significance ( $p = 0.06$  and  $0.09$ , respectively). Freestyle and Mosaic were not statistically significantly different. Mitroflow and Toronto SPV calcified significantly more than all other commercial valve tissues in this animal model.

Table 4. Statistical analysis of calcium data for each valve type.

|                           | CE<br>Duraflex | CE<br>ERIMOUNT | reestyle | GLUT<br>Only | Hancock<br>II | itroflow | Mosaic | CE<br>SAV |
|---------------------------|----------------|----------------|----------|--------------|---------------|----------|--------|-----------|
| CE Duraflex<br>(n=32)     |                |                |          |              |               |          |        |           |
| CE<br>PERIMOUNT<br>(n=35) | 0.62           |                |          |              |               |          |        |           |
| Freestyle<br>(n=30)       | 0.06           | 0.09           |          |              |               |          |        |           |
| GLUT-only<br>(n=11)       | <.01           | <.01           | <.01     |              |               |          |        |           |
| Hancock II<br>(n=16)      | 0.58           | 0.45           | 0.39     | <.01         |               |          |        |           |
| Mitroflow<br>(n=6)        | <.01           | <.01           | <.01     | 0.01         | <.01          |          |        |           |
| Mosaic (n=20)             | 0.01           | 0.02           | 0.21     | <.01         | 0.09          | <.01     |        |           |
| CE SAV<br>(n=20)          | 0.61           | 0.9            | 0.18     | <.01         | 0.75          | <.01     | 0.02   |           |
| Toronto SPV<br>(n=24)     | <.01           | <.01           | <.01     | 0.29         | <.01          | <.01     | <.01   | <.01      |

There was a statistically significant correlation between phospholipid levels and calcification ( $R = 0.63$ ,  $p=0.04$ ), where lower phospholipid levels were associated with lower calcium levels.

### 3.2(b) Histology

No signs of acute inflammation were found in either the implanted or host tissue. Signs of chronic inflammation were found in both implanted and host tissues, although it was frequently more severe in the implanted tissue. Mild to moderate collagen degeneration were noted intermittently in all groups tested. All unimplanted specimens appeared similar, suggesting collagen degeneration was occurring as a result of implantation.

While this experiment indicates that phospholipids contribute to the calcification of bioprosthetic tissue, there may be several other mechanisms which also contributed to the observed calcification. Residual aldehyde toxicity and mechanical and cellular factors (Schoen FJ, et al., *J Biomed Mater Res* 47:439-465 (1999); Grimm M, et al., *Surgery* 111:74-78 (1992); Grabenwoger M et al., *J*

*Tborac Cardiovasc Surg* **104**:14-21 (1992)) have all been implicated as factors in calcification.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes  
5 in light thereof will be suggested to persons skilled in the art and are to included within the spirit and purview of this application and are considered within the scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

**WHAT IS CLAIMED IS:**

- 1                   1.     A method of eliminating or reducing infection in a biological material,  
2     the method comprising removing a binding site contained in the material so that an infectious  
3     agent is prevented or inhibited from binding to the biological material.
- 1                   2.     The method of claim 1, wherein the infection is prion infection, and the  
2     infectious agent is prion protein.
- 1                   3.     The method of claim 1, wherein the biological material is bioprosthetic  
2     tissue.
- 1                   4.     The method of claim 3, wherein the structural integrity of the tissue is  
2     maintained.
- 1                   5.     The method of claim 3, further comprising contacting the bioprosthetic  
2     tissue with a preparation comprising a surfactant.
- 1                   6.     The method of claim 3, further comprising contacting the bioprosthetic  
2     tissue with a preparation comprising a surfactant and a denaturing agent.
- 1                   7.     The method of claim 6, wherein the surfactant is Tween 80.
- 1                   8.     The method of claim 6, wherein the denaturing agent is a protic  
2     solvent.
- 1                   9.     The method of claim 8, wherein the protic solvent is an alcohol.
- 1                   10.    The method of claim 9, wherein the alcohol is ethanol or isopropanol.
- 1                   11.    The method of claim 6, wherein the preparation further comprises an  
2     cross linking agent.
- 1                   12.    The method of claim 11, wherein the cross linking agent is an  
2     aldehyde.
- 1                   13.    The method of claim 12, wherein the aldehyde is formaldehyde or  
2     glutaraldehyde.

- 1                   14.     The method of claim 1, wherein the infectious agent binding site is  
2     comprised of phospholipid.
- 1                   15.     The method of claim 14, wherein the phospholipid is selected from the  
2     group consisting of phosphatidylinositol, phosphatidylethanolamine,  
3     gangliotetraosylceramide, phosphatidylserine, phosphatidylcholine, phosphatidic acid, and  
4     sphingomyeline.
- 1                   16.     The method of claim 14, further comprising contacting the tissue with  
2     a preparation including a phospholipase.
- 1                   17.     The method of claim 1, further comprising contacting the bioprosthetic  
2     tissue with a preparation comprising formaldehyde, ethanol, and Tween 80.
- 1                   18.     The method of claim 2, wherein the prion protein further comprises  
2     prion-precursor protein.
- 1                   19.     The method of claim 1, further comprising a terminal sterilization step.
- 1                   20.     The method of claim 1, further comprising washing the tissue to  
2     promote removal of the prion protein.
- 1                   21.     A method of treating a biological material, the method comprising  
2     removing a binding site contained in the material so that an unwanted protein is prevented or  
3     inhibited from binding to the biological material.
- 1                   22.     The method of claim 21, wherein the unwanted protein is selected from  
2     the group comprising alkaline phosphatase, Thy-1, and acetylcholinesterase.
- 1                   23.     A method of eliminating or reducing infection in a biological material,  
2     the method comprising removing a binding site comprising binding site a protein or  
3     polysaccharide, contained in the material so that an infectious agent is prevented or inhibited  
4     from binding to the biological material.
- 1                   24.     The method of claim 23, wherein the infection is prion infection, and  
2     the infectious agent is prion protein.

1                   25.     The method of claim 23, wherein the structural integrity of the tissue is  
2     maintained.

1                   26.     The method of claim 23, further comprising contacting the  
2     bioprosthetic tissue with a preparation comprising an enzyme that digests the binding site.

1                   27.     The method of claim 26, wherein the preparation comprises  
2     heparinase, in an amount effective to remove the binding site.

1                   28.     The method of claim 23, further comprising contacting the  
2     bioprosthetic tissue with a preparation comprising a solvent, a surfactant, or a chaotropic  
3     agent in an amount effective to extract the binding site from the tissue.

1                   29.     The method of claim 23, further comprising contacting the  
2     bioprosthetic tissue with a preparation that chemically derivatizes a polycationic site, thereby  
3     eliminating the binding site from the tissue.

1                   30.     The method of claim 23, wherein the binding sites has binding affinity  
2     to exogenous prion protein.

1                   31.     The method of claim 23, further comprising contacting the tissue with  
2     a preparation that has binding affinity for endogenous prion protein, so that a bound complex  
3     is formed between the preparation and the endogenous prion protein.

1                   32.     The method of claim 31, further comprising a washing step to remove  
2     the bound complex from the tissue.

1                   33.     A method of eliminating or reducing infection in a bioprosthetic tissue,  
2     the method comprising blocking a binding site contained in the tissue so that an infectious  
3     agent is prevented or inhibited from binding to the binding site.

1                   34.     The method of claim 33, wherein the infection of prion infection, and  
2     the infectious agent is prion protein.

1                   35.     The method of claim 33, wherein the structural integrity of the tissue is  
2     maintained.

1                   36.     The method of claim 33, wherein the blocking step further comprises  
2     contacting the bioprosthetic tissue with a preparation comprising one or more polysulfonated  
3     polyglycosides.

1                   37.     The method of claim 36, wherein the one or more polysulfonated  
2     polyglycosides are selected from a group consisting of pentosan polysulfate, sulfated  
3     colomycin, dextran sulfate, sulfated carageenans, and heparin/heparan sulfate.

1                   38.     The method of claim 36, wherein the contacting step is performed at a  
2     temperature of about 37° C.

1                   39.     The method of claim 33, wherein the contacting step promotes the  
2     dissociation of prion protein from the bioprosthetic tissue.

1                   40.     A method of eliminating or reducing infection in a bioprosthetic tissue,  
2     the method comprising blocking an infectious agent so that the infectious agent is prevented  
3     or inhibited from binding to a binding site in the tissue.

1                   41.     The method of claim 40, wherein the infection is prion infection, and  
2     the infectious agent is prion protein.

1                   42.     The method of claim 40, wherein the blocking step further comprises  
2     contacting the bioprosthetic tissue with a preparation comprising a compounds selected from  
3     tetrasubstituted porphyrin, polyanionic fungal agent, congo red, fast red, trypan red and  
4     combinations thereof.

1                   43.     The method of claim 40, wherein the method is performed before,  
2     during, or after fixation.

1                   44.     The method of claim 40, wherein the method is performed during  
2     bioburden reduction.

1                   45.     The method of claim 40, wherein the method is performed during final  
2     sterilization.

1                   46.     The method of claim 40, wherein the method is performed during  
2     packaging.

1                   47.     The method of claim 46, further comprising storing the tissue in the .  
2     preparation.

1                   48.     The method of claim 42, wherein the preparation further comprises one  
2     or more cross-linkable groups that prevent or inhibit dissociation of the one or more  
3     polysulfonated polyglycosides.

1                   49.     The method of claim 48, wherein the cross-linkable group is selected  
2     from a group consisting of lysine groups and azide moieties.

1                   50.     A method of eliminating or reducing calcification in a biological  
2     material, the method comprising removing a phospholipid calcium nucleation site contained  
3     in the material so that calcium is prevented or inhibited from binding to the biological  
4     material.

1                   51.     The method of claim 50, wherein the biological material is  
2     bioprosthetic tissue.

1                   52.     The method of claim 50, wherein the structural integrity of the  
2     bioprosthetic tissue is maintained.

1                   53.     The method of claim 51, further comprising contacting the  
2     bioprosthetic tissue with a preparation comprising a surfactant.

1                   54.     The method of claim 51, further comprising contacting the  
2     bioprosthetic tissue with a preparation comprising a surfactant and a denaturing agent.

1                   55.     The method of claim 54, wherein the surfactant is Tween 80.

1                   56.     The method of claim 54, wherein the denaturing agent is a protic  
2     solvent.

1                   57.     The method of claim 54, wherein the preparation further comprises an  
2     cross linking agent.

1                   58.     The method of claim 50, wherein the phospholipid is selected from the  
2     group consisting of phosphatidylinositol, phosphatidylethanolamine,

3 gangliotetraosylceramide, phosphatidylserine, phosphatidylcholine, phosphatidic acid, and  
4 sphingomyelin.

1                   59.     The method of claim 53, further comprising contacting the tissue with  
2 a preparation including a phospholipase.

1                   60.     The method of claim 50, further comprising contacting the  
2 bioprosthetic tissue with a preparation comprising formaldehyde, ethanol, and Tween 80.

1